Shares of Celcuity Inc. (NASDAQ:CELC – Get Rating) have received a consensus rating of “Buy” from the six research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $42.00.
Separately, Craig Hallum cut their target price on shares of Celcuity from $30.00 to $20.00 and set a “na” rating for the company in a report on Tuesday.
NASDAQ CELC traded down $0.16 on Tuesday, hitting $5.50. 3,982 shares of the company’s stock traded hands, compared to its average volume of 64,905. The company has a current ratio of 34.06, a quick ratio of 34.06 and a debt-to-equity ratio of 0.21. Celcuity has a 1-year low of $5.31 and a 1-year high of $33.01. The firm’s 50-day moving average price is $7.68 and its two-hundred day moving average price is $11.20. The firm has a market capitalization of $82.06 million, a PE ratio of -2.48 and a beta of 1.64.
Several large investors have recently bought and sold shares of CELC. Royal Bank of Canada increased its holdings in Celcuity by 9.5% in the 2nd quarter. Royal Bank of Canada now owns 6,296 shares of the company’s stock worth $151,000 after acquiring an additional 546 shares in the last quarter. American International Group Inc. increased its holdings in Celcuity by 18.5% in the 3rd quarter. American International Group Inc. now owns 5,292 shares of the company’s stock worth $95,000 after acquiring an additional 825 shares in the last quarter. Deutsche Bank AG increased its holdings in Celcuity by 17.5% in the 3rd quarter. Deutsche Bank AG now owns 5,579 shares of the company’s stock worth $100,000 after acquiring an additional 830 shares in the last quarter. California State Teachers Retirement System increased its holdings in Celcuity by 23.2% in the 4th quarter. California State Teachers Retirement System now owns 5,225 shares of the company’s stock worth $69,000 after acquiring an additional 984 shares in the last quarter. Finally, BNP Paribas Arbitrage SA increased its holdings in Celcuity by 405.2% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock worth $33,000 after acquiring an additional 1,471 shares in the last quarter. 38.30% of the stock is owned by hedge funds and other institutional investors.
Celcuity Company Profile (Get Rating)
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
- Get a free copy of the StockNews.com research report on Celcuity (CELC)
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Beware The Rebound In Home Depot
- Time to Ride These 3 Mid Cap Momentum Plays
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.